Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: Results of NCIC CTG MA.14

Allan Lipton, Judy Anne W. Chapman, Laurence Demers, Lois E. Shepherd, Lei Han, Carolyn F. Wilson, Kathleen I. Pritchard, Kim E. Leitzel, Suhail M. Ali, Michael Pollak

Research output: Contribution to journalArticle

45 Scopus citations

Abstract

Purpose: We investigated the association of bone-only relapse with a pretreatment marker of bone resorption: serum beta C-terminal telopeptide (B-CTx) of type I collagen. Methods: Pretreatment serum B-CTx concentrations were determined from 621 of 667 patients with primary breast cancer enrolled onto the NCIC CTG MA.14 phase III adjuvant trial of tamoxifen with or without octreotide. Recurrence-free survival (RFS) was a secondary end point; the focus here was bone-only relapse. We analyzed continuous or categorical (.71 ng/mL cut point) serum B-CTx in stepwise forward multivariate Cox regression, adjusted for trial stratification factors. We also examined B-CTx and bone relapse by pretrial chemotherapy status. Results: At median 7.9 years follow-up, 123 of 621 patients experienced recurrence; 19 (3.1%) of 621 had bone-only recurrence, and 47 (7.5%) of 621 had bone plus other sites of recurrence. Larger pathologic tumor size (P = .001) and elevated continuous and categorical serum B-CTx were associated with shorter bone-only RFS (both P = .02) when added to a model with factors significant in the main trial analyses (hazard ratio [HR], 3.43 and 3.50, respectively; 95% CI, 1.20 to 9.77 and 1.26 to 9.75, respectively). The univariate HR for B-CTx was 2.80 (95% CI, 1.05 to 7.48; P = .03). Elevated serum B-CTx was also associated with shorter bone-only RFS (P = .02) when added to a model with factors significant in the main trial analyses. Serum B-CTx level was not associated with any other type of recurrence. Serum B-CTx was not significantly different for patients who underwent pretrial chemotherapy, compared with those who did not (P=.27), nor did pretrial chemotherapy affect bone relapse (P = .48 for bone only; P = .76 for bone with other relapse). Conclusion: Higher pretreatment serum B-CTx was a significant predictor of shorter RFS for bone-only metastasis. Increased bone resorption creates an environment that promotes growth of breast cancer cells.

Original languageEnglish (US)
Pages (from-to)3605-3610
Number of pages6
JournalJournal of Clinical Oncology
Volume29
Issue number27
DOIs
StatePublished - Sep 20 2011

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lipton, A., Chapman, J. A. W., Demers, L., Shepherd, L. E., Han, L., Wilson, C. F., Pritchard, K. I., Leitzel, K. E., Ali, S. M., & Pollak, M. (2011). Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: Results of NCIC CTG MA.14. Journal of Clinical Oncology, 29(27), 3605-3610. https://doi.org/10.1200/JCO.2010.31.5069